Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.68 USD | -5.10% | -12.24% | +58.17% |
Business Summary
Number of employees: 122
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
DNA Medicines
100.0
%
| 10 | 100.0 % | 1 | 100.0 % | -91.89% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 10 | 100.0 % | 1 | 100.0 % | -91.89% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Jacqueline Shea
CEO | Chief Executive Officer | 58 | 19-03-24 |
Peter Kies
DFI | Director of Finance/CFO | 60 | 02-05-31 |
Chief Tech/Sci/R&D Officer | - | 07-01-31 | |
Jeffrey Skolnik
CTO | Chief Tech/Sci/R&D Officer | - | 16-10-11 |
Michael Sumner
CTO | Chief Tech/Sci/R&D Officer | 59 | 22-06-26 |
Laurent Humeau
CTO | Chief Tech/Sci/R&D Officer | 57 | 14-02-17 |
Thomas Hong
IRC | Investor Relations Contact | - | - |
Cheryl Elder
LAW | General Counsel | - | - |
Shawn D. Bridy
PRN | Corporate Officer/Principal | - | 18-05-23 |
Maggie Campbell
AUD | Comptroller/Controller/Auditor | - | 06-02-28 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Simon Benito
CHM | Chairman | 79 | 03-11-30 |
Lota Zoth
BRD | Director/Board Member | 64 | 17-12-31 |
Jay Shepard
BRD | Director/Board Member | 66 | 20-01-14 |
Wendy Yarno
BRD | Director/Board Member | 68 | 17-12-05 |
David Weiner
FOU | Founder | 67 | 83-06-28 |
Jacqueline Shea
CEO | Chief Executive Officer | 58 | 19-03-24 |
Roger Dansey
BRD | Director/Board Member | 68 | 21-05-12 |
Ann Miller
BRD | Director/Board Member | 66 | 19-03-24 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 0 | 1,091 | 0 | 1,082 ( 99.18 %) | 98.51 % |
Stock B | 1 | 25,329,333 | 24,953,826 ( 98.52 %) | 0 |
Company contact information
Inovio Pharmaceuticals, Inc.
660 West Germantown Pike Suite 110
19462-1111, Plymouth Meeting
+267 440 4200
http://www.inovio.comSector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+58.17% | 251M | |
-1.42% | 41.52B | |
+42.15% | 39.9B | |
+1.97% | 38.83B | |
-14.19% | 26.05B | |
+1.82% | 23.78B | |
-24.55% | 18.26B | |
-4.07% | 11.65B | |
+21.36% | 11.53B | |
+8.20% | 11.2B |
- Stock Market
- Equities
- INO Stock
- Company Inovio Pharmaceuticals, Inc.